Overview

Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

This is a phase 3, multicentre, non-inferiority, randomised factorial trial. The purpose of this study is to study the efficacy and safety of nedaplatin versus cisplatin, and capecitabine versus fluorouracil in induction docetaxel, cisplatin, and fluorouracil (TPF) plus concurrent chemoradiotherapy with cisplatin (P-RT) in locoregionally advanced nasopharyngeal carcinoma (NPC).

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Air Force Military Medical University, China
Cancer Hospital of Guangxi Medical University
Cancer Hospital of Guizhou Province
Fifth Affiliated Hospital, Sun Yat-Sen University
First People's Hospital of Foshan
Fourth Military Medical University
Henan Cancer Hospital
Hunan Cancer Hospital
Jilin Provincial Tumor Hospital
Peking University
Second Affiliated Hospital of Soochow University
The First Affiliated Hospital of Guangdong Pharmaceutical University
Tongji Hospital
Wuhan Union Hospital, China
Xiangya Hospital of Central South University
Zhejiang Cancer Hospital

Treatments:

Capecitabine
Cisplatin
Docetaxel
Fluorouracil
Nedaplatin